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Abstract 
Fusion imaging (PET/CT), widely used 
in the developed countries, allows the 
identification of different lesions at the 
molecular level, enabling the emergence of 
a new field of advanced medicine - 
"molecular imaging". For example, marking 
with a radiotrasor of a nucleic acid chain 
component allows the identification of the 
cancer at the molecular level and its 
treatment by radioimuno - scintigraphic 
techniques. Having a great sensitivity in the 
early detection of some lesions in a wide 
spectrum of pathology, Nuclear Medicine 
procedures are much sought by the 
clinicians. 
Keywords: cancer, cyclotron, 
radionuclides, spinal tumors 
Introduction 
Cancer begins at subcelular molecular 
level by altering a gene that controls cell 
growth and behavior; in particular there is a 
marked increase in DNA synthesis and an 
exaggerated local consumption of glucose as 
an energetic support for anarchic cell 
multiplication. These amendments are 
being “propagated” little by little, so that 
after a certain period of time (years) during 
wich the disease usually progresses 
asymptomatically , tissues or organs come 
to be involved. When the number of cancer 
cells is large enough to be detected visually 
by conventional techniques (X-ray, 
ultrasound, CT, MRI), the disease has 
already passed the stage where it can be 
treated successfully. The challenge of 
medical activity is to detect cancer before 
the onset of clinical symptoms and 
dissemination in other organs and to 
establish an early effective treatment. 
Cancer  is one of the main causes of 
mortality in the world. Recent statistical 
studies conducted under the auspices of the 
World Health Organization (WHO) show 
that 1 in 9 women will develop some form 
of breast cancer, 1 in 7 men will develop a 
form of prostate cancer, and 1 of 10 male 
will develop lung cancer. Effective 
treatment depends mainly on early 
detection of tumor process (8). 
Materials and Methods 
When diagnosed by the methods existing 
today in our country, including the high 
performance imagistic explorations, cancer 
can not be cured. The established treatment 
- surgery, chemotherapy or radiation may 
provide, in relation to the evolutive stage of 
the desease a survival not exceeding 4-5 
years (2).  Medical imaging is a top field of 
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medicine that includes a group of modern 
medical techniques with different 
principles, which have in common the fact 
that provide diagnostic data through the 
image of the anatomical systems, internal 
organs or injuries. These imaging 
techniques can be grouped into: 
- Anatomical (structural) techniques: 
ultrasound, computed tomography (CT), 
magnetic resonance imaging (MRI), 
angiography, digital radiography; 
- Functional (metabolic) techniques: 
planar scintigraphy, tomoscintigraphy 
(SPECT), monoclonal antibody 
imunoscintigraphy, positron emission 
tomography (PET). 
Anatomic and metabolic imaging fusion: 
integrated PET-CT, SPECT-CT, PET-RM 
systems are high performance techniques 
that enable in a single view both the 
pathological metabolic process examination 
and its precise location by co-registering the 
two categories of information (13, 14). Due 
to its increasingly large expansion and wide 
introduction into diagnostic and settlement  
protocols around the world, we will refer 
next to PET-CT technique. The PET-CT 
is an imaging technique that realizes the 
early detection of cancer by visualizing the 
excessive glucose consumption in the 
cancer cells (PET) and the anatomical 
location of the precise process by 
simultaneous PET and CT scanning. Since 
1991 over 2000-3000 equipments have been 
installed over the world. WHO estimates a 
need of approximately one PET equipment 
at 1 million inhabitants.   
PET technique is based on marking a 
normal constituent of the body (e.g. - 
deoxiglucose, an analogue of glucose) with 
a positron emission radiotrasor ( 18F, 14C, 
16O, 13N but usually 18F ) that after iv 
injection is distributed throughout the 
body, depending on the distribution 
properties of the radiolabeled constituent. 
Once injected into the body, the positrons 
emitted by radionuclide decay migrate to 
short distance into the tissues, lose some of 
the energy, slow their motion, and 
annihilate after the collision with present 
electrons. The annihilation process will give 
two gamma photons emitted in opposite 
directions (1800), with an energy of 511 
keV each. Both radiations can then be 
detected by forming a ring of detectors 
around the patient so that it becomes 
possible mapping the distribution of 
positron-emitting isotope into the body. In 
this way can be studied the distribution of 
an extremely large number of substances 
whose metabolism is affected in various 
pathological conditions (2, 12, 13). By far 
the most widely used positron-emitting 
radionuclide is 18F  coupled with 
deoxiglucose - analogue of glucose. 
Metabolically active cancer cells  will 
capture the labeled glucose about 30-40 
times higher than the adjacent healthy cells. 
The computerized system of the facility 
that detects the photons emitted from the 
positron annihilation with an electron, 
allows the space identification of the 
positronic radiotracer fixation place and also 
viewing the pathological process (9). The 
positron emitting radiotracers used for PET 
examination are included in the table 
below: 
 
Positron emitting 
radiotracer Physical T1/2
 
18F 110 min. 
11C 20 min. 
13N 10 min. 
15O 2 min. 
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Figure 1 FDG – PET normal appearance 
 
Because of the short physical half-life, 
positron emitting radionuclides need to be 
produced on site in a medical cyclotron 
(baby cyclotron). There are positron 
emitting radionuclides produced in a 
generator, e.g. -  68Ga, which by coupling 
with different peptides allow to assess and 
conduct therapeutic setting for 
neuroendocrine tumors, but other clinical 
applications are currently in the research 
stage (10). 
The method was developed in the '70s 
(Phelps and Hoffman) and it has been used 
for two decades  predominantly in the 
clinical research of various cellular 
processes at molecular level by 
incorporating the positronic isotop into 
different  messenger molecules (enzymes, 
hormones, antibodies, peptides and 
oligonucleotide). Imaging of apoptosis, 
neurotransmitters and neoangiogenesis 
have been translated from experimental 
evidence into clinical practice (Figure 1). 
The remarkable progress in molecular 
imaging determined W. Wagner jr. (from J. 
Hoppkins Clinic - Baltimore) to assert that 
"the molecular medicine has revolutionized 
modern medicine, the nuclear medicine 
comes to revolutionize molecular 
medicine". In 1998, Townsend had the idea 
to combine (overlay) the metabolic PET 
images with the anatomic CT images, 
making accurate anatomical localization of 
the lesions through what is called "fusion 
image". The first integrated PET-CT 
equipments produced by major companies 
have been introduced into clinical practice 
around 2000, being widely accepted by the 
medical community. 
The PET-CT equipment through a 
single examination allows to obtain a fusion 
image that contains both metabolic 
information (PET) and precise anatomical 
details (CT). 
The PET-CT main indications are:  -
detection and indication of the malignant or 
benign substrate of various tumors; -
determining the actual extension of 
malignant tumors, the preoperative and 
postherapeutic   staging;  -differentiating 
the postoperative fibrosis, the residual post 
irradiation tumor necrosis or the relapse;  -
establishing the tumor prognosis compared 
with the level of glucose uptake and the 
histological grade; -directing the therapeutic 
surgical approaches: minimal surgery, CT-
guided percutaneous ablation,   
chemoembolization; -directing the selective 
biopsy by identifying viable component of 
the partially necrotic tumors (8). 
The necessary equipment includes: 
cyclotron for obtaining the positron emitting 
radioisotopes; radiopharmacy laboratory for 
radiolabelling the active molecules (fluorine 
deoxiglucose, 11C - methionine, 11C - 
thymidine, 18F - deoxythymidine, 18F - 
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choline, etc.). It is possible to purchase the  
radiotrasor  from a radiopharmacy, but the 
latter must be at a reasonable distance from 
PET-CT unit because of the very short half-
life of radionuclides  and it is only possible for 
radiotrasors tagged with 18F  (T1/2 = 110 
min., compared to  11C with T1/2 = 20 min. 
or 15O with T1/2 = 2 min.!) (Figure 2). 
The PET/CT scan combines the 
metabolic details of a PET scan (tumor cell 
activity, tumor viability  etc.) with the 
anatomical details  offered by a CT scan (size 
and location of tumor, mass, anatomical 
relationships etc.), giving a more accurate 
image than PET or CT used separately. The  
PET examination begins with intravenous 
injection of FDG (18-fluorine 
dezoxiglucose), a glucose-like substance 
which is attached to the F18 isotope. The 
metabolically active tissues  or these with 
abnormally high rate of multiplication 
(tumors) consume much higher amounts of 
the radioactive sugar. The radiotracer 
accumulation leads to gamma rays emissions 
that are converted by computer into images. 
These images indicate "hot" areas signaling 
tissues with high metabolic activity (abnormal 
increased multiplication rate) because cancer 
cells consume more sugar / energy than other 
tissues or organs. The CT scan is based on 
the absorption in varying degrees of the X-
rays by the examined structures and on the 
computerized  data processing to obtain the 
thin sections that can be reconstructed three-
dimensional reproducing detailed images of 
body structures. The entire examination 
usually takes 30 minutes, providing detailed 
and accurate information that enables 
physicians to provide a quick, correct and 
complete diagnosis. 
 
 
 
 
Figure 2 The integrated PET-CT equipment 
 
 
 
Figure 3 67 years old male patient. Rx and CT 
examinations: solitary pulmonary nodule. The 
indication of PET-CT: assessing the 
malignant/benign substrate of the lesion. Anatomo-
pathological examination: small cell carcinoma 
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In oncology, the PET/CT investigation 
offers the ability to early diagnose, locate, 
monitor and control the development of 
cancer. With PET-CT, surgeons, 
oncologists and other specialists will be able 
to detect cancer more accurately, to assess 
recurrences, to make a complete and 
accurate staging, to assess the patient's likely 
response to therapy and to monitor more 
effectively the results of chemotherapy and 
radiotherapy. In oncology, PET-CT 
provides vital diagnostic information that 
allows monitoring of treatment outcomes 
and often helps avoid surgery (4). 
In neurology and neurosurgery, PET - 
CT is used to identify areas of the brain that 
cause seizures and to determine whether 
surgery is a viable option. Also, this 
technology allows diagnosis of Alzheimer's 
disease at a stage when the disease can still 
be controlled with medication.  
Before examination, patients are asked: -  
not to eat nor drink anything (or to drink 
only plain water) at least 6 hours before the 
examination, because it could affect the 
results (the ban also refers to sugarfree 
chewing gum, mints, candies and drinks of 
any kind); - if they take drugs, they should 
drink only as much water as it is necessary 
to swallow them; - to minimize their 
physical activity on the day they are 
examined (gymnastics, jogging, etc.) as it 
might affect the capture of the radionuclide; 
- to bring with them on the day they are 
examined previous CT scan, X-ray, 
scintigraphic or MRI examinations, tumoral 
markers results,  anatomo-pathological test 
results and  hospital discharge papers they 
have (as written reports, images or CDs); - 
to announce in advance whether they are 
diabetic, to allow physician consultation on 
the preparation and conduct of 
examination;  before the actual examination 
begins their blood glucose level is measured 
anyway. When recording high blood 
glucose levels which persist even after being 
taken measures to low them, the 
investigation can not be done; - to 
announce whether they are febrile; - to 
announce the existence or suspicion of 
pregnancy or nursing status; - to call the 
physician if they have questions about the 
scheduled procedure (15). 
The examination will begin with a test to 
determine blood glucose level. Patients will 
then receive an injection containing a small 
amount of radioactive glucose (radioactive 
sugar), which will be distributed 
throughout the body. The radiotracers used 
for PET/CT scan lose their radioactivity 
very quickly (within two to three hours) 
and only very small doses are injected. Six 
to eight hours after injection, the remaining 
radioactivity is negligible. In most cases, 
patients will have to wait about an hour for 
radioactive drug to be distributed in the 
body.  
 
 
 
Figure 4 78 years old woman with operated 
squamous cell lung adenocarcinoma (post-
pneumonectomy status). The indication of PET-CT: 
staging. PET-CT examination: tumoral relapse; right 
lung metastasis, on the front and left side of the T5 
vertebral body 
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About 60 minutes after the injection, 
patients will go to the toilet to urinate. 
Patients will be asked to stand still during 
the scan because movement can affect the 
outcome of the investigation. During the 
scan patients breathe normally. During the 
acquisition of the images they will not feel 
anything unusual, except table movements, 
as some areas of the body are scanned. 
Throughout the examination the patients 
will be monitored by an operator and they 
may communicate with him through the 
microphone and through the cameras. The 
PET-CT scan takes between 20 and 30 
minutes. The examination procedure may 
differ depending on the examined area (20). 
The risks and precautions during the 
examination are not negligible and should 
be known. Except the restraint during the 
examination, there is recorded no special 
sensation like pain, annoying noises, 
temperature differences, etc. There were 
never reported unwanted side reactions 
after intravenous administration of FDG, 
required for carrying out the PET / CT 
examination. There are no 
contraindications for the FDG 
administration and only in cases of severe 
renal failure or high blood sugar level that 
not falls within lower values of 180-200 
mgr/dl, the examination is not made, 
because these conditions make it impossible 
to correctly use the radiotracer. Sometimes, 
intravenous injection of the substance can 
be difficult. In this case there is a catheter 
inserted in advance. Any state of pregnancy, 
suspected or found, is a contraindication to 
the examination. In this case, the necessity 
of investigation should be determined by 
mutual agreement with the treating 
physicians. Breast-feeding should be 
discontinued for at least 6 hours after 
completion of investigation. Renal failure 
causes a reduction in quality of PET / CT 
scan images, although it is not a 
contraindication to  perform the 
examination. Patients wearing orthopaedic 
prostheses, pacemakers, implanted arterial 
or venous prostheses, etc., are not exposed 
to any risk, but it is appropriate to inform of 
their existence the physician that records 
the medical history (22). 
After the administration of FDG follows 
an average wait of 60 minutes to ensure 
optimal distribution of the substance into the 
body. The image acquisition time with PET – 
CT equipment is about 30 minutes, but in 
some cases may be extended, depending on 
the disease (e.g.- melanomas) or on the 
pursuit of certain issues. The last part of 
procedure lasts about 15 minutes (16). 
The presence of the integrated PET-CT 
equipment in Romania allows detection of 
cancer (and other diseases) to debut before 
the effective dissemination into the entire 
body, with maximum therapeutic efficiency 
(9). 
 
 
 
Figure 5 37 years old female patient, presenting 
physical fatigue, low grade fever, left laterocervical 
swelling / The indication of PET / CT: diagnostic-
staging. Anatomo-pathological examination: 
Hodgkin’s lymphoma 
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Figure 6 39 years old female, presenting fever, 
physical fatigue, pruritus, palpable supraclavicular  
lymph nodes, thoracic pains. The indication of PET-
CT: staging. PET-CT examination: FDG uptake is 
observed in several coastal, vertebral and axillary 
lymph nodes outbreaks. Supraclavicular lymph 
nodes biopsy: Hodgkin’s lymphoma 
 
 
Figure 7 51 years old male with non-Hodgkin’s 
lymphoma with mediastinal, lung, spinal and 
cerebral dissemination, that followed multiple 
courses of chemotherapy. The indication of PET-
CT: evaluation 6 months after the last course of 
chemotherapy. PET-CT examination : axillary 
lymphatic dissemination after chemotherapy for 
non-Hodgkin’s lymphoma 
 
The World Health Organization and the 
International Agency for Fight against 
Cancer recommends a PET-CT facility at 
approx. 1-2000000 inhabitants (19). 
 
 
Figure 8 43 years old female patient with right 
mastectomy 2 years ago for breast cancer, with 
vertebral, lung and liver metastatic diseminations. 
Clinical issues: difuse bone pains, pronounced at 
sternal and verterbral level. The indication of PET-
CT : new staging 
Cases presentation  
We present some clinical cases of  patients 
treated in the Neurosurgery Clinic of "Dr. 
Carol Davila" Central Universitary Military 
Emergency Hospital and investigated PET-
CT at Euromedic - Fundeni Clinic (Figure  
8, 9, 10, 11, 12, 13, 14). 
 
Before chemotherapy 
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After chemotherapy 
 
Figure 9 67 years old female with metastatic breast 
cancer. The indication of PET-CT: assessing the 
response   chemotherapy 
 
 
Figure 10 52 years old male patient with lung 
cancer: multiple bone metastases in PET and PET / 
CT (thoraco-abdominal contrast CT scan  in  
normal range) 
 
 
 
 
 
 
 
 
 
 
Figure 11 T11 compression in 63 years old  female 
with multiple osteoblastic lesions 
 
 
 
Figure 12 63 years old  female with breast cancer 
and secondary disseminations at T10 epidural and 
vertebral body and pedicle level 
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Figure 13 52 years old  female with colon cancer and 
metastatic process involving the T11 posterior body 
and posterior elements, with epidural extension 
 
 
Figure 14 Tumoral mass with epidural extension 
through the left T11 intervertebral foramen in a 51 
years old female patient with lymphoma 
Discussion  
The goal of surgery is to improve the 
quality of life as it is not always possible to 
cure the illness itself. It aims to: 
- decompress the nerves trying to 
improve the patients neurological status;  
- stabilize and relief pain, so the patient 
to be able to keep upright and walk;  
- obtain a histo-pathological diagnosis 
followed by a specific oncological treatment 
(23). 
Currently the vertebral and spinal 
pathology benefits from the contribution of 
new diagnostic techniques that have been 
developed and applied in the last two 
decades. Generally these techniques are 
known as imaging techniques that have in 
common the fact that provide diagnostic 
information on the lesion substrate using 
computerized processed images. In the 
order of their clinical applicability have 
been imposed: magnetic resonance imaging 
(MRI), computerized tomography (CT), 
tomoscintigraphy (SPECT) and positron 
emission tomography (PET-CT). These 
computerized techniques have 
revolutionized the neuroradiology replacing 
or restricting the applicability of 
conventional radiological diagnostic 
methods: plain or contrast radiography 
(myelography), conventional tomography 
and arteriography (22).  
PET-CT scan shows a lot of benefits 
compared with other commonly used 
imaging means: 
• determines how widespread the   
disease is;                                                                                   
• indicates the location of the tumor to 
execute biopsy, surgical treatment or 
planning of treatment; 
• analyzes the response to and efficiency 
of the therapy;  
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• detects traces of residual disease or 
relapse;  
• helps to avoid invasive diagnostic 
procedures. 
Being fully compatible with the 
oncological radiotherapy systems 
(Micromultileaf, CyberKnife, 
Tomotherapy),  PET / CT allows the 
urgent development of optimized treatment 
plans for selective irradiation of 
metabolically active tumoral tissue, fully 
preserving healthy tissues (8). 
Conclusions  
The investigation and treatment of 
vertebral and spinal tumoral injuries is 
necessary to comply with the best 
neurosurgical conduct requirements. These 
requirements are imposed by current 
knowledge of acquisitions in the field of 
spinal surgery, as reflected in literature. 
Their main purpose is to avoid the 
numerous errors and complications that 
may occur during treatment. Meeting these 
requirements will bring more clarity to the 
doctor-patient relationship, particularly in 
cases where after the neurosurgical 
treatment occurre  litigations related to the 
quality of the medical care (17). 
In spinal tumoral pathology the 
investigations are required to clarify the 
location and, if possible, the etiology of the 
lesion. The precise location  dictates the 
approach path and the suspected etiology 
allows selection of an appropriate surgical 
technique. Also, for the surgery decision is 
necessary that the location of the lesion to 
be consistent with the neurological 
symptoms, ie the location to explain the 
neurological syndrome (21). 
The patient should be exhaustively 
investigated, meaning not a lot of abusive 
and aimless investigations, but a full 
appropriate investigation protocol, to 
establish an accurate diagnosis. In line with 
current international standards, the 
methods of diagnosis in spinal pathology 
should focus on minimally invasive  
investigations that provide maximum 
information (12). 
References 
1.  Aryanpur J, Ducker T - Multilevel Lumbar 
Laminotomies: An Alternative to Laminectomy in the 
Treatment of Lumbar Stenosis, Neurosurg. 1999, 26: 
429-433.  
2. Arseni C, Simionescu M - Patologia vertebro-
medulara neurochirurgicala, Ed.Medicala1968,267-268. 
3. Black P., Kaye A. – Operative Neurosurgery. 
Churchill Livingstone 2000; 879-898: 
4. Connelly S., Mc Khann G., Huang  J., Chondhry T. 
– Fundamentals of Operatives Techniques in 
Neurosurgery. Thieme 2001; 
5. Deshayes P, Louvel JP - Le canal lombaire étroit, La 
Rev Pract (Paris) nr.5, 1992, 569-572. 
6. DePalma A, Rothman RH, Lewinnek G, Carole S. 
Anterior interbody fusion for severe cervical disc 
degeneration. Surg Gynecol Obstet. 1999; 134: 755-758. 
7. Flynn TB. Neurologic complications of anterior 
cervical interbody fusion. Spine. 1982; 7: 536-539. 
8. Fraser JF, Härtl R. Anterior approaches to fusion of 
the cervical spine: a metaanalysis of fusion rates. J 
Neurosurg Spine. 2007; 6: 298–303. 
9. Ganz JC - Lumbar Spinal Stenosis: Postoperative 
Results in Terms of Preoperative Posture -Related Pain, 
J of Neurosurgery1990,72:71-74. 
10. Greenberg MS - Handbook Neurosurgery, vol 1, 
Greenberg Graphics, 1997, 207-213 
11. Henderson CM, Hennesy R, Shuey H. Posterior 
lateral foraminotomy for an exclusive operative 
technique for cervical radiculopathy. A review of 846 
consecutively operated cases. J Neurosurg. 1983; 13: 
504-512. 
12. Matz PG, Ryken TC, Groff MW, Vresilovic EJ, 
Anderson PA, Heary RF, Holly LT, Kaiser MG, 
Mummaneni PV, Choudhri TF, Resnick DK. 
Techniques for anterior cervical decompression for 
radiculopathy. J Neurosurg Spine . 2009; 11: 183–197. 
13. Matz PG, Anderson PA, Kaiser MG, Holly LG, 
Groff MW, Heary RF, Mummaneni PV, Ryken TC, 
Choudhri TF, Vresilovic EJ, Resnick DK. Introduction 
and methodology: guidelines for thesurgical 
management of cervical degenerative. Journal of 
Neurosurgery: Spine. 2009; 11(2): 101-103. 
14. Michael G. Fehlings, and Babak Arvin. Surgical 
 
 
 
M. Mitrică et al          The Value of Fusion Imaging 
 
 
 
management of cervical degenerative disease: the 
evidence related to indications, impact, and outcome. J 
Neurosurg Spine. 2009; 11: 97–100. 
15.  Netter F. Neurologic and neurosurgical disorders, 
Second Edition. The CIBA GEIGY Corp. 1992,184- 
189. 
16.  Silvers HR, Lewis PJ - Decompressive Lumbar 
Laminectomy for Spinal Stenosis, J 
Neurosurg,1993,78:695-701. 
17. Simpson JM, Silveri CP, Simeone FA, Balderston 
RA. Cervical disc disease and the keyhole 
foraminotomy: Proven efficacy at extended long term 
follow-up. Spine. 2008; 8(2): 115-120. 
18.  Skalpe IO, Sortland O - Myelography, Tano, 
1989,57-61. 
19. Taveras JM - Neuroradiology, Third Ed. 1996,823-
825 
20. Tuite GF, Stern JD, Doran SE - Outcome after 
Laminectomy for Lumbar Spinal Stenosis. Part 1: 
Clinical Correlations, J Neurosurg. 1994, 81: 699-706. 
21. Tervonen H, Niemelä M, Lauri ER, Bäck L, Juvas 
A, Räsänen P, Roine RP, Salmi T, Vilkman E, Aaltonen 
LM. Dysphonia and dysphagia after anterior cervical 
decompression. J Neurosurg Spine. 2007;7: 124–130. 
22. Zdeblick TA, Zou D, Warden KE, McCabe R, Kunz 
D, Vanderby R. Cervical stability after foraminotomy. J 
Bone Joint Surg. 1992; 74: 22-27. 
23. Youmans J. R. – Neurological Surgery, Fourth 
Edition, W. B.SaundersCompany,2000. 
 
